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ABSTRACT
Introduction: Hemolysis is considered a class
effect and a rare adverse event that can occur
following therapy with human normal
immunoglobulin for intravenous administration
[i.e., intravenous immunoglobulin (IVIG)].
Anti-A/B isoagglutinins (also referred to as
isohemagglutinins) originating from donor
plasma are present in polyvalent
immunoglobulin G (IgG) products and are
considered a probable risk factor for hemolysis.
We hypothesized that, by excluding plasma from
donors with high isoagglutinin titers, the final
IVIG product would have a meaningful reduction
in anti-A/B isoagglutinin titers.
Methods: A method for screening donor
plasma for anti-A isoagglutinins using an
automated indirect agglutination test (IAT)
was developed. A cut-off for donor plasma
exclusion was defined. Industry-scale donor
plasma pools and final IVIG product were
prepared according to the manufacturing
process of Privigen (CSL Behring, Berne,
Switzerland; human 10% liquid IVIG). Anti-A/B
isoagglutinin content in pooled plasma and
final IVIG product was measured by IAT, direct
agglutination test, and a flow cytometry-based
assay [fluorescence-activated cell sorting (FACS)
anti-A].
Results: Screening of plasma from 705 donors
identified 48 (6.8%) donors with high anti-A
isoagglutinin titers in plasma (IAT
agglutination score C2? in a 1:200 pre-
dilution). Exclusion of plasma from these
donors resulted in a one-titer-step reduction
of anti-A isoagglutinin in pooled plasma,
confirmed by a twofold anti-A isoagglutinin
concentration reduction measured by FACS
anti-A (1,352 vs. 2,467 lg/g IgG). When the
same screening and exclusion were applied to
industrial-scale plasma pools (resulting in the
exclusion of plasma from 5% of donors), anti-A
isoagglutinins were reduced by one titer step in
the final IVIG product. Anti-B isoagglutinins
were also reduced by one titer step, as many
donors with high anti-A isoagglutinins also
have high anti-B.
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Conclusion: Reduction of anti-A/B
isoagglutinin titers in IVIG products on an
industrial scale is feasible through
implementation of anti-A donor screening,
which may reduce the risk of hemolysis
following IVIG therapy.
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INTRODUCTION
Antibody-mediated hemolytic reaction is a
known, rare class effect of immunoglobulin
(Ig) G therapy administered intravenously [i.e.,
intravenous immunoglobulin (IVIG)]. Most of
the reported IVIG-related cases are subclinical
and self-limited; however, severe and/or serious
cases have been reported [1, 2]. Known risk
factors for IVIG-related hemolysis are: non-O
blood group, high doses of IVIG therapy, and an
underlying inflammatory state [1–5].
Characterization of risk factors and
development of prevention methods are
currently complicated by the absence of a
commonly accepted definition of clinically
relevant hemolysis.
In the majority of IVIG-related cases of
hemolysis, anti-A/B isoagglutinins (also
referred to as isohemagglutinins) have been
suspected or shown to be involved [5–7]. Anti-
A/B isoagglutinins originating from donor
plasma are passively transferred during
administration of IVIG. The role of anti-A/B
isoagglutinins is supported by the very low
occurrence of hemolysis in patients with O
blood group. Patients with A blood group tend
to have higher incidence of IVIG-related
hemolytic reactions than B blood group
patients [4], which suggests greater relevance
of anti-A isoagglutinin. Isoagglutinin
concentrations are lower in some IVIG
products prepared by ethanol fractionation, as
that process leads to significant reduction of
isoagglutinins [6]. Modern Ig purification
processes are designed to keep the full
antibody repertoire of the donated plasma and
thus do not reduce isoagglutinins. An increase
in the frequency of reported hemolytic events
with IVIG in recent years [4] may be in part due
to the introduction of these modern Ig
purification processes, leading to higher
isoagglutinin titers, in addition to the
generally increased use of IVIG products.
Screening and exclusion of donors with high
anti-A/B isoagglutinin titers proved to be
effective in preventing hemolytic reaction
after ABO-incompatible platelet transfusion
[7]. Screening for either anti-A or anti-B
isoagglutinin alone may be sufficient to
identify candidate donors for exclusion, as
high titers of anti-A/B isoagglutinins tend to
correlate in individual donors [8, 9]. To develop
a screening program that can be used on an
industrial scale, it is necessary to define a cut-off
anti-A/B isoagglutinin level that produces
isoagglutinin titer reduction in the final IVIG
product with exclusion of a relatively small
proportion of donors.
Versions of the indirect agglutination tests
(IAT) and direct agglutination tests (DAT) [10]
have been used to detect anti-A/B isoagglutinins
in donor plasma [5, 7, 9] and IVIG products [8].
All the methods have limitations, and the inter-
assay variability remains high [8, 11]; therefore,
most results are not directly comparable,
particularly when obtained with different
methods. International reference material
[specified in the European Pharmacopoeia
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(PhEur)] has been established for DAT in IVIG
products only [10]. The lack of overall
standardization adds to the difficulty of
developing measures of isoagglutinin
reduction and of evaluating their effectiveness.
Privigen (CSL Behring, Berne, Switzerland) is a
10% liquid preparation of polyclonal human IgG
for intravenous administration, stabilized with
L-proline [12]. Privigen is indicated for
replacement therapy in patients with primary
immunodeficiency and for immunomodulation
in patients with immune thrombocytopenic
purpura in the United States (US) [13]. In Europe,
the list of indications also includes secondary
immunodeficiency and selected immune-
mediated diseases, such as chronic inflammatory
demyelinating polyneuropathy, Guillain–Barre´
syndrome, and Kawasaki disease [14].
We hypothesized that the titer of anti-A/B
isoagglutinins in IVIG products can be reduced
by donor screening and exclusion of plasma
with high anti-A isoagglutinin titers. Here, we
report the effect of such anti-A isoagglutinin
donor screening on anti-A/B isoagglutinin titers
in industry-scale donor plasma pools and the
final IVIG product (i.e., Privigen).
METHODS
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
Method Development: Anti-A
Isoagglutinin Donor Screening
Donors were randomly selected for screening
from regular plasmapheresis donors at CSL
Plasma centers in the US. Plasma donors gave
written consent that their plasma may be used
for research purposes.
Indirect Isoagglutinin Test in Gel Cards
Anti-A isoagglutinin titer in plasma of
individual donors was measured by IAT in gel
cards (IAT-GC) containing microcolumns filled
with dextran acrylamide gel and rabbit anti-
human-IgG antibodies [ID-Micro Typing
SystemTM (ID-MTS); Ortho Clinical Diagnostics
(OCD), Rochester, NY, USA]. The testing was set
up as a high-throughput, automated assay,
using a Freedom EVO programmable unit
(Tecan Group Ltd., Ma¨nnedorf, Switzerland)
for sample predilution and a ProVueTM
instrument (OCD) for sample processing.
Plasma samples were prediluted 1:200 with
0.9% sodium chloride from primary tubes into
barcoded secondary tubes. Prediluted samples
were transferred into the ID-MTS gel cards and
incubated at 37 C with 0.8% ready-to-use
suspension of A1 blood group red blood cells
(RBC; Affirmagen; OCD) according to the
manufacturer’s instructions, followed by
centrifugation. Slower sedimentation of RBC
in the gel due to agglutination caused by
reaction with the anti-human IgG allowed
discriminating between samples with different
anti-A isoagglutinin titers. RBC agglutination
strength was detected automatically for each
sample, according to a predefined RBC
localization pattern: a well-defined pellet
indicating no agglutination (agglutination
score 0), predominantly localized in the lower
half of the tube (1?), dispersed throughout the
tube (2?), predominantly localized in the upper
half of the tube (3?), solid band of RBC on the
top of the gel (4?; Fig. 1). The endpoint anti-A
isoagglutinin titer was defined as the
reciprocal of the highest dilution with
agglutination score C1? in a 1:200 pre-
dilution. Samples with mixed readout were re-
analyzed.
Donor plasma minipools were prepared by
mixing 20 lL of plasma from each donor
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included in the development study (thus
mimicking plasma pool preparation during
Privigen production), with exclusion of donor
plasma with agglutination scores C1?, C2?, or
C3?. Anti-A isoagglutinin titer in minipools
was measured by IAT-GC and an optimized IAT
method in microtiter plates (IAT-PhEur/MTP)
[10]. Double serial dilutions were used for
titration; therefore, one titer step corresponded
to a twofold change in isoagglutinin titer. Non-
anti-A-screened plasma (a minipool prepared
from plasma of all tested donors) was used for
comparison in all tests.
Flow Cytometry-Based Anti-A Isoagglutinin
Binding Assay
The concentration of anti-A isoagglutinin in
donor plasma minipools was measured with a
flow cytometry-based anti-A isoagglutinin
binding assay [fluorescence-activated cell
sorting (FACS) anti-A]. Prediluted plasma
samples were incubated for 60 min at room
temperature with A blood group RBC
(a standard RBC preparation that was obtained
from a single donor and was used in all tests).
RBC-bound anti-A isoagglutinin was detected
by subsequent incubations with biotinylated
anti-human-IgG antibodies (no cross-reaction
with IgM; Nordic Immunological Laboratories,
Tilburg, the Netherlands) and with
fluorescently labeled streptavidin. The median
fluorescence intensity was quantified with a
FACSCantoTM II cell analyzer (Becton-
Dickinson AG, Allschwil, Switzerland). Anti-A
isoagglutinin concentration was calculated
based on a standard curve prepared with
affinity-purified polyclonal human anti-A
antibodies and was expressed in lg/g of total
IgG.
Implementation on a Production Scale:
Donor Plasma Pools and the Final IVIG
Product
All plasma pools and final IVIG product lots
were prepared according to the Privigen
manufacturing process. Plasma pool lots were
prepared by mixing up to 12,000 plasma
Fig. 1 Indirect agglutination test in gel cards. Red blood
cell localization patterns resulting from the indirect
agglutination test in ID-Micro Typing SystemTM gel cards
(Ortho Clinical Diagnostics, Rochester, NY, USA).
Agglutination scores below the tubes indicate agglutination
strength, from 0 (no agglutination) to 4? (strongest
agglutination). The rightmost column shows an example of a
mixed readout (MF)
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donations per lot using normal US source
plasma obtained from CSL Plasma. Each final
IVIG product lot was prepared from 3–5 plasma
pool lots (16,000–60,000 plasma donations).
The anti-A-screened and non-anti-A-
screened lots of both plasma pools and final
IVIG product were prepared with or without
implementation of the anti-A donor screening,
respectively. The anti-A-screened plasma pool
lots used for anti-A/B isoagglutinin testing were
drawn randomly and do not necessarily match
the plasma pool lots (also anti-A-screened) that
were used for production of the anti-A-screened
final IVIG product.
Anti-A/B Isoagglutinin Detection in Plasma
Pools
Titers of anti-A/B isoagglutinins were measured
in 120 anti-A-screened and 72 non-anti-A-
screened plasma pool lots by IAT-GC (ID-Card
Coombs Anti-IgG; Bio-Rad Laboratories-DiaMed
GmbH, Cressier, Switzerland), according to the
manufacturer’s instructions. Undiluted plasma
pool samples were titrated by double serial
dilution below the anticipated detection limit
of isoagglutinin. The dilutions were transferred
into microcolumns attached to gel cards and
incubated for 15 min at 37 C with A1 or B
blood group RBC (ID-DiaCell ABO; Bio-Rad
Laboratories–DiaMed GmbH), followed by
centrifugation. The agglutination strength in
each dilution was scored according to the RBC
localization patterns as described above. The
highest dilution with agglutination score C1?
was considered the endpoint titer.
Anti-A/B Isoagglutinin Detection in the Final
IVIG Product
The concentration of anti-A/B isoagglutinins
in the final IVIG product was measured
according to PhEur 2.6.20, methods A and B
[10]. A total of 30 anti-A-screened Privigen
lots, 651 historical non-anti-A-screened
Privigen lots and additional 30 non-anti-A-
screened lots of final IgG products [Privigen
or Hizentra (CSL Behring, Berne,
Switzerland), IgG purified by the same
process, but formulated as 20% solution for
subcutaneous use] were analyzed.
Method A: indirect agglutination assay in
microtiter plates (IAT-PhEur/MTP) Twofold serial
dilutions of the final IVIG product (starting
from 30 g/L of total Ig) were incubated for
30 min at 37 C with either A1 or B blood group
RBC in a microtiter plate. After removing non-
specific IgG in a washing step (3 washes with
centrifugation for 1 min at 300g at room
temperature), anti-human globulin reagent
PelikloonTM (Sanquin Reagents, Amsterdam,
the Netherlands) was added and mixed well
with the RBC. Agglutination of the sedimented
RBC was assessed macroscopically by inspection
of the microtiter plate well. The highest dilution
with visible RBC agglutination was considered
the endpoint titer.
Method B: direct agglutination test Twofold
serial dilutions of the final IVIG product
(starting from 50 g/L of total Ig) were mixed
with papain-treated A1 or B blood group RBC in
a microtiter plate, followed by centrifugation
for 1 min at 80g at room temperature. After
centrifugation the microtiter plate was placed at
70 angle, and agglutination strength was
assessed by RBC localization pattern:
streaming vs. non-streaming. The highest
dilution with visible RBC agglutination (non-
streaming pattern) was considered the endpoint
titer.
FACS anti-A Anti-A isoagglutinin
concentration in 10 anti-A-screened Privigen
lots and 10 non-anti-A-screened lots of final
IgG products (Privigen or Hizentra) was
measured by the FACS anti-A assay as
described above.




A total of 705 plasma samples collected from
randomly selected individual donors were
tested for anti-A isoagglutinin titers using
IAT-GC. All reported agglutination scores for
single-donor plasma are based on a 1:200 pre-
dilution. A small proportion of donors (n = 48;
6.8%; Table 1, excluded donors) were
identified as having high anti-A isoagglutinin
levels [agglutination score 2? (5.4%) or 3?
(1.4%); Fig. 2]. The rest of the donors were
either negative or weakly positive for anti-A
isoagglutinin [agglutination score 0 (81%) or
1? (12.2%)]. No donors with agglutination
score 4? were identified (Fig. 2).
Plasma-donor minipools were prepared based
on results of the anti-A donor screening.
Exclusion of donor plasma with agglutination
score 3? did not result in a measurable anti-A
reduction (as determined by IAT-GC; Fig. 3),
confirmed by a decrease of only about 20% in
anti-A isoagglutinin concentration measured by
FACS anti-A. Exclusion of donor plasma with
agglutination scores C2? resulted in reduction
Table 1 Plasma minipools based on the anti-A donor screening
Minipool 1 Minipool 2 Minipool 3 Minipool 4
Minipool composition All donors Medium, low or negative scores Low or negative scores Negative scores
Included donors, n 705 695 657 571
Excluded donors, n 0 10 48 134
% of all donors 0.0 1.4 6.8 19.0
Anti-A agglutination score(s) N/A 3?, 4? 2?, 3?, 4? 1?, 2?, 3?, 4?
Minipool titration: serial double dilutions tested by IAT-GC (OCD)
Anti-A score(s)
Titer 1:8 3? 3? 2? 1?
Titer 1:16 2? 2? 2? 1?
Titer 1:32 2? 1? 1? (–)
Titer 1:64 1? 1? (–) (–)
Titer 1:128 (–) (–) (–) (–)
Minipools tested by FACS for anti-A (lg/g IgG)
Mean (SD) 2,467 (134) 2,006 (207) 1,352 (110) 673 (241)
Ratio vs. non-anti-A-screened
plasma, %
100.0 81.3 54.8 27.3
Minipools were prepared by mixing equal amounts (20 lL) of each donor plasma thus mimicking a manufacturing pool (Minipool
1). Donors with anti-A agglutination scores 1?, 2?, 3? (at 1:200 pre-dilution) were gradually excluded (Minipools 2–4), and the
effect of reduction in anti-A content was shown by titrating each minipool in serial double dilutions
FACS anti-A Flow cytometry-based anti-A isoagglutinin binding assay, IAT-GC indirect agglutination test in gel cards, IgG
Immunoglobulin G, n number of donors, N/A not applicable, OCD Ortho Clinical Diagnostics (Rochester, NY, USA), SD
standard deviation
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of the anti-A isoagglutinin titer compared with
non-anti-A-screened plasma by one titer step.
The decrease in anti-A isoagglutinin titer was
confirmed by an approximately twofold
reduction of anti-A isoagglutinin concentration
measured by FACS anti-A (1,352 ± 110 vs.
2,467 ± 134 lg/g IgG). Exclusion of all anti-A-
positive donor plasma reduced the anti-A
isoagglutinin titer by 2 titer steps and anti-A
isoagglutinin concentration measured by FACS
anti-A by approximately fourfold.
Exclusion of donor plasma with agglutination
scores C2? resulted in a relevant reduction in
anti-A/B isoagglutinins by one titer step, with an
Fig. 2 Distribution of anti-A in donor population
(method development). Anti-A isoagglutinin titers in
plasma of a representative number of randomly selected
donors (N = 705) were assessed by the indirect agglutina-
tion test in gel cards [Ortho Clinical Diagnostics (OCD),
Rochester, NY, USA]. Distribution of donors with
agglutination scores from 0 to 4? (in a 1:200 pre-dilution)
are shown as columns. No donors with agglutination score
4? were found. The corresponding endpoint titers from
serial double dilutions of individual plasma samples are
shown below the graph. IAT-GC Indirect agglutination test
in gel cards
Fig. 3 Anti-A isoagglutinin titers in donor plasma mini-
pools (method development). Plasma minipools were
prepared from plasma samples of all screened donors
(N = 705), donors with medium, low or negative anti-A
(agglutination score B2?; n = 695), donors with low or
negative anti-A (agglutination score B1?; n = 657), or
from plasma of anti-A-negative donors only (n = 571).
Anti-A isoagglutinin titers of each minipool were deter-
mined by the indirect agglutination test in gel cards (IAT-
GC) obtained from Ortho Clinical Diagnostics (OCD,
Rochester, NY, USA; black columns) or Bio-Rad Labora-
tories-DiaMed GmbH (DiaMed; gray columns), or in
microtiter plates (IAT-PhEur/MTP; light-gray columns)
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acceptable rate of donor exclusions (6.8%).
Exclusion of donors with plasma agglutination
score 3? would not result in a meaningful
reduction of anti-A/B isoagglutinins. Exclusion
of all anti-A positive donors with scores C1?
would lead to exclusion of approximately 20% of
donor plasma and was considered not feasible at
production scale. Thus, the cut-off agglutination
score of C2? was selected for further
investigation on a production scale.
Implementation on a Production Scale:
Donor Plasma Pools and the Final IVIG
Product
The anti-A isoagglutinin donor screening was
applied to the Privigen manufacturing process to
test whether anti-A/B isoagglutinin reduction
could be achieved in plasma pools and/or in the
final IVIG product. Testing of a large number of
donors confirmed the isoagglutinin distribution in
the donor population seen in the experimental
study. Of 188,337 screened donors, 94.9% had low
anti-A isoagglutinin titers (agglutination score 1?
or 0) and 5.1% had either medium (2?; 3.6%) or
high (3?; 1.5%) anti-A isoagglutinin titers.
Anti-A/B Isoagglutinin Concentration
in Plasma Pools
Both the highest and most frequent anti-A
isoagglutinin titer observed in 120 anti-A-
screened plasma pool lots was 1 titration step
lower than in 72 non-anti-A-screened lots (1:32
vs. 1:64; Fig. 4). The highest anti-B isoagglutinin
titer observed in the same set of anti-A-screened
plasma pool lots was one titration step lower
than in the non-anti-A-screened lots (1:16 vs.
1:32; Fig. 4).
Anti-A/B Isoagglutinin Concentration
in the Final IVIG Product
In 30 anti-A-screened Privigen lots analyzed by
IAT-PhEur/MTP, both the highest (1:16 in 10%
of lots) and the most frequent (1:8 in 90% of
lots) anti-A isoagglutinin titers were reduced by
1 titer step compared with 651 historical, non-
anti-A-screened lots (Fig. 5). Similarly, a two-
step reduction of the highest anti-B
isoagglutinin titer was observed in the anti-A-
screened set (1:8 in 16.7% of lots) versus non-
anti-A-screened set (1:32 in 0.2% of lots). The
Fig. 4 Anti-A/B isoagglutinin titers in anti-A-screened and
non-anti-A-screened donor plasma pool lots (production
scale). Donor plasma pool lots were prepared either with
implementation of the anti-A donor screening (anti-A-
screened; black columns; 120 lots) or from plasma of all
available donors (non-anti-A-screened; gray columns; 72
lots). Each ﬁnal intravenous immunoglobulin product lot
was prepared from 16,000 to 60,000 plasma donations.
Anti-A/B isoagglutinin titers of each lot were determined
by the indirect agglutination test in gel cards (DiaMed
GmbH, Cressier, Switzerland). PP Plasma pool
22 Biol Ther (2014) 4:15–26
geometric mean of anti-A (1:8.6 vs. 1:13.8) and
anti-B isoagglutinin titers (1:4.5 vs. 1:7.3) was
reduced by approximately one titer step.
The highest anti-A and anti-B isoagglutinin
titers measured by DAT in 30 anti-A-screened
Privigen lots (1:16–1:32 for anti-A; 1:8–1:16 for
anti-B) were reduced by 1 titer step vs. 30 ‘‘non-
screened’’ Privigen lots (1:16–1:64 for anti-A;
1:8–1:32 for anti-B), with the same median titers
in both sets (1:32 and 1:16 for anti-A and anti-B
isoagglutinin, respectively). The reference
preparations established for the DAT in PhEur
were assayed in each test run and complied with
the PhEur specifications (1:32–1:64; data not
shown). All IVIG product lots met the specified
titers for anti-A and anti-B.
Reduction of anti-A isoagglutinin
concentration upon implementation of the
anti-A donor screening was confirmed by FACS
anti-A in 10 anti-A-screened and 10 non-anti-A-
screened Privigen lots. The mean anti-A
isoagglutinin concentration was reduced
1.37-fold (1,220.3 lg/g IgG in the non-anti-A-
screened lots vs. 893.2 lg/g IgG in anti-A-
screened lots), which corresponds to
approximately 0.5 titer steps.
DISCUSSION
We have developed an anti-A donor screening
assay based on measurement of anti-A
Fig. 5 Anti-A/B isoagglutinin titers in anti-A-screened and
non-anti-A-screened ﬁnal intravenous immunoglobulin
(IVIG) product lots (production scale). Final IVIG product
lots were prepared either with implementation of the
anti-A donor screening (anti-A-screened; black columns) or
from plasma of all available donors (non-anti-A-screened;
gray columns). Each ﬁnal IVIG product lot was prepared
from 16,000 to 60,000 plasma donations. Anti-A/B
isoagglutinin endpoint titers of 30 anti-A-screened and
651 historical, non-anti-A-screened Privigen lots were
determined by the indirect agglutination test in microtiter
plates (IAT-PhEur/MTP). The 30 anti-A-screened
Privigen lots and additional 30 non-anti-A-screened lots
of the ﬁnal immunoglobulin G products (Privigen or
Hizentra; both CSL Behring, Berne, Switzerland) were
analyzed by the direct agglutination test (DAT)
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isoagglutinin titers in donor plasma with IAT.
A cut-off agglutination score C2? in a 1:200
pre-dilution of plasma allowed exclusion of a
small proportion of donated plasma
(approximately 5%) with the highest anti-A
isoagglutinin titers. The anti-A donor screening
resulted in anti-A isoagglutinin titer reduction by
one titer step both in industry-scale plasma pool
lots and in the final IVIG product (i.e., Privigen).
A similar one-titer-step reduction was observed
for anti-B isoagglutinin titers, consistent with
the known correlation of high anti-A and anti-B
isoagglutinin titers in O blood group donors
[8, 9]. These results strongly suggest that testing
donors for anti-A isoagglutinin alone is sufficient
for reduction of both anti-A and anti-B
isoagglutinin in final IVIG products.
We presumed that a single test would be
sufficient for each donor, rather than testing
each donation, as isoagglutinin titers are not
expected to change much over time [15]. All
subsequent plasma donations from a donor
with isoagglutinin titers above the cut-off
would then be excluded from the production
of IVIG, but not necessarily from the
production of other plasma products, such as
albumin or coagulation factors. The anti-A
donor screening assay proved to be compatible
with the Privigen production process on an
industrial scale, suggesting that donor screening
can be routinely applied to IVIG production.
Comparison of the anti-A-screened and non-
anti-A-screened plasma pool and final IVIG
product lots was purely descriptive due to the
very different numbers of lots, time of plasma
collection and homogeneity of the donor
groups. Nonetheless, we consider this
comparison to be valid, as the same
standardized plasma collection and storage
conditions, as well as isoagglutinin detection
methods, were used for all samples. We
concluded that by donor screening and
exclusion of plasma from donors with high
anti-A isoagglutinin titers, both anti-A and
anti-B isoagglutinins can be reduced by one
titer step (i.e., the concentration can be reduced
by 50%).
Privigen and most other IVIG products
consist of purified IgG with only trace
amounts of IgM, which excludes the majority
of anti-A/B isoagglutinin molecules. The
screening assay used here may have led to
exclusion of plasma from donors with high
concentrations of IgM isoagglutinins only. By
excluding these donors without further
screening, we adopted a conservative
approach, even though the anti-A
isoagglutinin titer of the final IVIG product
would not have been affected by inclusion of
plasma from such donors.
The clinical relevance of a one-titer-step anti-
A/B reduction in IVIG is currently unknown
and can be determined only in large trials.
Hemolytic events tend to occur during high-
dose IVIG therapy (1–2 g/kg), whereas very few
cases have been reported in patients with
primary immunodeficiency, who are usually
treated with lower IgG doses (0.4–0.8 g/kg) [4].
This observation supports our hypothesis that a
reduction of isoagglutinins by 1 titer step (or to
50% of the initial concentration) may be
clinically important. A one-titer-step reduction
was detected by IAT, while DAT and FACS anti-
A results suggested a lesser reduction. All these
methods have their limitations; the reason for
the discrepancy is currently unknown. A
prospective, observational clinical study is
warranted to evaluate the efficacy of donor
plasma screening on IVIG hemolytic risk.
Implementation of isoagglutinin screening
as described here is possible for plasma
collectors operating large plasmapheresis
centers. This screening has been implemented
by CSL Plasma in all its plasma collection
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centers. However, multiple plasma sources are
typically used for IVIG production, which may
include recovered plasma obtained from local
organizations. Implementation of a new
screening program for these plasma sources
may be difficult and is not entirely within the
reach of IVIG manufacturers. Therefore, new
methods for anti-A/B isoagglutinin
quantification are currently in development
(such as FACS anti-A).
CONCLUSION
This study confirms, using the example of
Privigen, that reduction of anti-A/B
isoagglutinin titers in IVIG products through
anti-A donor plasma screening is feasible on an
industrial scale. Implementation of
isoagglutinin donor plasma screening with
exclusion of donations with high titers may
reduce the risk of hemolysis in patients treated
with IVIG.
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